Keep in mind that whether you are considering supplements or repurposed prescription medications, each compound has unique risks and benefits. When researching, always check with your personal physician given that nattokinase has risks involving bleeding. Keep up on the latest material published by Dr. Mark Moyad who published the initial work on the SAM cocktail and who some consider an authority on the topic of supplements. Also watch the FLCCC website as they are actively researching repurposed drugs and cancer at this time.
I read your book "Surviving Cancer, COVID-19, and Disease: The Repurposed Drug Revolution" last year with great interest. I am summarizing and translating some of it for two people I know who were diagnosed with cancer and have a question regarding the following section on Metformin. You write:
> In 2005, Dr. Josie M. Evans published a study that examined 314,000 people in Tayside, Scotland.31 Some 11,000 were diagnosed with type II diabetes. Some were treated with metformin, and others were not. Nine hundred twenty-three were later diagnosed with malignant cancer. The chance of getting cancer for those taking metformin was roughly 40% less than non-metformin users.
My question is: Where exactly do you get the "roughly 40% less" figure from?
Also I submitted quite a bit of feedback via my Kindle for small grammatical errors. Are you reviewing those? Is a new edition planned? Is there anything we could do to help with that?
Thanks for the heads up for things to keep in mind! Well to discuss with one's Doctor if there is significant history to raise this concern. You are appreciated!
Thank you - Consider the following from a PubMed 2019 study:
"Metformin is a widely used drug in today’s prescriptions by physicians due to its specific effects in treating and curing type II diabetes. Diabetes is a common disease that may occur throughout human life, and can increase the likelihood of the occurrence of various types of cancer, such as colon, rectum, pancreas and liver cancers, compared to non-diabetic patients. Metformin inhibits mTOR activity by activating ATM (ataxia telangiectasia mutated) and LKB1 (liver kinase B1) and then adenosine monophosphate-activated kinase (AMPK), and thus prevents protein synthesis and cell growth. Metformin can activate p53 by activating AMPK and thereby ultimately stop the cell cycle. Given the potential of metformin in the treatment of cancer, it can be used in radiotherapy, chemotherapy and to improve the response to treatment in androgen derivatives (ADT), and also, according to available evidence, metformin can also be used to prevent various types of cancers. Generally, metformin can: 1) reduce the incidence of cancers, 2) reduce the mortality from cancers, 3) increase the response to treatment in cancer cells when using radiotherapy and chemotherapy, 4) optimize tumor movement and reduce the malignancy, 5) reduce the likelihood of relapse, and 6) reduce the damaging effects of ADT. Therefore, this drug can be used as a complementary therapeutic agent for cancer treatment and prevention. In this review, we have summarized the data from various experimental and clinical studies and highlight the possible potential effects of metformin on cancer therapeutic responses."
Another noteworthy quote from the same PubMed study:
"For example, the results of the Taiwan National Health Insurance Data Survey, which included a community of 12,005 patients taking metformin from 2000 to 2007 and a population of 4,597 patients taking other oral medications, indicated that using metformin reduces the chance of any type of cancers up to 88%."
very interesting and thank you. Do you feel that nattokinase would be an acceptable substitute for a daily aspirin or not?
Keep in mind that whether you are considering supplements or repurposed prescription medications, each compound has unique risks and benefits. When researching, always check with your personal physician given that nattokinase has risks involving bleeding. Keep up on the latest material published by Dr. Mark Moyad who published the initial work on the SAM cocktail and who some consider an authority on the topic of supplements. Also watch the FLCCC website as they are actively researching repurposed drugs and cancer at this time.
Hi Dr. Hope,
I read your book "Surviving Cancer, COVID-19, and Disease: The Repurposed Drug Revolution" last year with great interest. I am summarizing and translating some of it for two people I know who were diagnosed with cancer and have a question regarding the following section on Metformin. You write:
> In 2005, Dr. Josie M. Evans published a study that examined 314,000 people in Tayside, Scotland.31 Some 11,000 were diagnosed with type II diabetes. Some were treated with metformin, and others were not. Nine hundred twenty-three were later diagnosed with malignant cancer. The chance of getting cancer for those taking metformin was roughly 40% less than non-metformin users.
The study you are referring to is this one: https://www.bmj.com/content/330/7503/1304.long
My question is: Where exactly do you get the "roughly 40% less" figure from?
Also I submitted quite a bit of feedback via my Kindle for small grammatical errors. Are you reviewing those? Is a new edition planned? Is there anything we could do to help with that?
Warm regards!
Thanks for the heads up for things to keep in mind! Well to discuss with one's Doctor if there is significant history to raise this concern. You are appreciated!
Thank you - Consider the following from a PubMed 2019 study:
"Metformin is a widely used drug in today’s prescriptions by physicians due to its specific effects in treating and curing type II diabetes. Diabetes is a common disease that may occur throughout human life, and can increase the likelihood of the occurrence of various types of cancer, such as colon, rectum, pancreas and liver cancers, compared to non-diabetic patients. Metformin inhibits mTOR activity by activating ATM (ataxia telangiectasia mutated) and LKB1 (liver kinase B1) and then adenosine monophosphate-activated kinase (AMPK), and thus prevents protein synthesis and cell growth. Metformin can activate p53 by activating AMPK and thereby ultimately stop the cell cycle. Given the potential of metformin in the treatment of cancer, it can be used in radiotherapy, chemotherapy and to improve the response to treatment in androgen derivatives (ADT), and also, according to available evidence, metformin can also be used to prevent various types of cancers. Generally, metformin can: 1) reduce the incidence of cancers, 2) reduce the mortality from cancers, 3) increase the response to treatment in cancer cells when using radiotherapy and chemotherapy, 4) optimize tumor movement and reduce the malignancy, 5) reduce the likelihood of relapse, and 6) reduce the damaging effects of ADT. Therefore, this drug can be used as a complementary therapeutic agent for cancer treatment and prevention. In this review, we have summarized the data from various experimental and clinical studies and highlight the possible potential effects of metformin on cancer therapeutic responses."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497052/
Another noteworthy quote from the same PubMed study:
"For example, the results of the Taiwan National Health Insurance Data Survey, which included a community of 12,005 patients taking metformin from 2000 to 2007 and a population of 4,597 patients taking other oral medications, indicated that using metformin reduces the chance of any type of cancers up to 88%."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6497052/